Serum galectin-3 as a biomarker of progression of idiopathic pulmonary fibrosis treated with nintedanib

IF 2.4 Q2 RESPIRATORY SYSTEM Respiratory investigation Pub Date : 2025-03-18 DOI:10.1016/j.resinv.2025.03.006

Yasuhiko Koga , Mitsuru Motegi , Akihiro Ono , Yoshimasa Hachisu , Mitsuyoshi Utsugi , Noriaki Sunaga , Atsushi Takise , Mari Sato , Tomohito Kuwako , Takashi Osaki , Manabu Ueno , Seishi Yoshimi , Koichi Yamaguchi , Takeshi Hisada , Kyoichi Kaira

{"title":"Serum galectin-3 as a biomarker of progression of idiopathic pulmonary fibrosis treated with nintedanib","authors":"Yasuhiko Koga , Mitsuru Motegi , Akihiro Ono , Yoshimasa Hachisu , Mitsuyoshi Utsugi , Noriaki Sunaga , Atsushi Takise , Mari Sato , Tomohito Kuwako , Takashi Osaki , Manabu Ueno , Seishi Yoshimi , Koichi Yamaguchi , Takeshi Hisada , Kyoichi Kaira","doi":"10.1016/j.resinv.2025.03.006","DOIUrl":null,"url":null,"abstract":"<div><div>Both serum and bronchoalveolar lavage fluid levels of galectin-3 (Gal-3) are elevated in patients with idiopathic pulmonary fibrosis (IPF). Phase II study on inhaler with Gal-3 inhibitor for IPF has been ongoing. In this study, 30 treatment-naive patients of IPF were prospectively enrolled and their sera were stored before and after nintedanib treatment. Though Gal-3 levels tended to increase after nintedanib treatment, in some patients, Gal-3 levels decreased immediately after the treatment. Patients whose serum Gal-3 levels decreased 1 month after nintedanib treatment tended to experience a smaller annual decline in forced vital capacity (FVC) than patients with increased Gal-3 levels. Furthermore, the rate of change in Gal-3 levels 1 month after nintedanib treatment positively correlated with the rate of annual FVC decline, whereas that of other fibrotic markers did not correlate with the rate of annual FVC decline.</div><div>This study suggested that a decline in serum Gal-3 levels immediately after nintedanib treatment may predict less progression of IPF treated with nintedanib.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 3","pages":"Pages 394-398"},"PeriodicalIF":2.4000,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory investigation","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212534525000310","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

Both serum and bronchoalveolar lavage fluid levels of galectin-3 (Gal-3) are elevated in patients with idiopathic pulmonary fibrosis (IPF). Phase II study on inhaler with Gal-3 inhibitor for IPF has been ongoing. In this study, 30 treatment-naive patients of IPF were prospectively enrolled and their sera were stored before and after nintedanib treatment. Though Gal-3 levels tended to increase after nintedanib treatment, in some patients, Gal-3 levels decreased immediately after the treatment. Patients whose serum Gal-3 levels decreased 1 month after nintedanib treatment tended to experience a smaller annual decline in forced vital capacity (FVC) than patients with increased Gal-3 levels. Furthermore, the rate of change in Gal-3 levels 1 month after nintedanib treatment positively correlated with the rate of annual FVC decline, whereas that of other fibrotic markers did not correlate with the rate of annual FVC decline.

This study suggested that a decline in serum Gal-3 levels immediately after nintedanib treatment may predict less progression of IPF treated with nintedanib.

查看原文